Gender does not influence event-free survival in patients with ischaemic heart disease undergoing non-emergency coronary angiography : a single centre analysis by Jankowski, Piotr et al.
Kardiologia Polska 2007; 65: 5
Gender does not influence event-free survival 
in patients with ischaemic heart disease undergoing
non-emergency coronary angiography. 
A single centre analysis
Piotr Jankowski1, Kalina Kawecka-Jaszcz1, Danuta Czarnecka1, Leszek Bryniarski1, 
Małgorzata Brzozowska-Kiszka1, Beata Kieć-Wilk1, Grzegorz Dymek1, Ewa Kopacz1, 
Tadeusz Królikowski1, Dariusz Dudek2
1 1st Department of Cardiology, Collegium Medicum Jagiellonian University, Cracow, Poland 
2 2nd Department of Cardiology, Collegium Medicum Jagiellonian University, Cracow, Poland
Original article
Address for correspondence:
Małgorzata Brzozowska-Kiszka MD, I Klinika Kardiologii CMUJ, ul. Kopernika 17, 31-501 Kraków, tel.: +48 12 424 73 00, 
fax: +48 12 424 73 20, e-mail:  mbkiszka@interia.pl
Received: 21 October 2006. Accepted: 06 February 2007.
A b s t r a c t
Background: Although gender-related differences in cardiovascular risk in patients with acute coronary syndromes have
been investigated several times in Poland, there are few data on the effects of gender on management of patients with stable
ischaemic heart disease (IHD). In addition, available data on the prognosis in this condition in men and women are also scarce. 
Aim: To assess gender-related differences in treatment and event-free survival in patients with IHD undergoing non-
emergency coronary angiography. 
Methods: 960 consecutive patients with IHD undergoing coronary angiography were included. Study end points were
ascertained over 4.5-year follow-up in 925 patients, of whom 187 were women and 738 were men. The primary end-point
consisted of cardiovascular death, myocardial infarction, stroke, cardiac arrest, PCI, CABG or heart transplantation. 
Results: Female gender was independently related to higher prescription rate of beta-blockers [odds ratio 1.89 (95% CI 
1.08-3.29)], ACE inhibitors [1.47 (1.01-2.16)] and calcium antagonists [1.65 (1.08-2.53)] at the time of coronary angiography. On
the other hand, female gender was not independently related to the probability of PCI [1.01 (0.69-1.49)] or CABG [0.91 
(0.57-1.48)]. We did not find any gender-related difference in the risk of the primary end point [hazard ratio 0.94 (95% CI 
0.67-1.34)] or the three predefined secondary end points. 
Conclusions: Female gender was independently related to a higher prescription rate of beta-blockers, ACE inhibitors and
calcium antagonists. No gender-related revascularisation was found in respect of myocardial revascularisation. Gender was not
an independent factor affecting event-free survival in patients with IHD undergoing non-emergency coronary angiography.
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Introduction
Ischaemic heart disease (IHD) is the most
common single cause of death in developed
countries. Numerous studies have explored the
existence of different management practices in
women and men in the setting of acute coronary
syndromes [1-6]. Recently, several studies concerning
gender-related differences in stable angina have been
published [7, 8]. Some [1-3, 6, 8], but not all [4, 5, 7],
of the studies showed that women are investigated
and treated less aggressively than men. Moreover,
some analyses indicated that women with IHD have
worse prognosis than their male counterparts
[2, 3, 6, 8-10]. However, other investigators found no
gender-related difference in cardiovascular risk in
patients with IHD [4, 5, 7, 11, 12]. It was also
suggested that the difference in mortality, although
present in univariate analysis, disappears after
multiple adjustments [9, 13]. Several analyses showed
even higher risk in men [1, 14].
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Although gender-related differences in
cardiovascular risk in patients with acute coronary
syndromes have been investigated several times in
Poland [6, 14-17] there are few data on the effect of
gender on management of patients with stable IHD in
Poland. Also contemporary information about
prognosis in this condition in men and women is
similarly scarce. Taking all the above into account the
present analysis was designed to assess the gender-
related differences in treatment and event-free survival




Consecutive patients with coronary artery disease
(CAD) undergoing non-emergency coronary
angiography between 1998 and 2001 and hospitalised
in our department were eligible for our study.
Physicians followed clinical guidelines when
considering coronary angiography [18]. We defined
CAD as the presence of at least one significant
stenosis (>50%) in the epicardial arteries or
myocardial infarction (MI) or revascularisation
procedure in the history. We excluded from the
analysis all patients with acute MI within a week prior
to angiography, patients who received intravenously
antianginal or antihypertensive agents within 12 hours
or catecholamines within 24 hours prior to coronary
angiography, and those with primary pulmonary
hypertension. Patients with haemodynamically
significant valvular heart disease as assessed during
catheterisation or echocardiography and patients
with congenital heart disease as well as those with
atrial fibrillation/flutter at the time of examination
were also excluded.
Baseline data collection
Fasting blood samples were taken before coronary
angiography for the analysis of lipids as well as
glycaemia and creatinine levels. Diabetes was defined
as a fasting blood glucose level of 7.0 mmol/l or more
and/or the use of an antidiabetic drug. No
differentiation was made between type 1 and type 2
diabetes during analysis due to the low number of
patients with type 1 diabetes. Participants with total
cholesterol levels ≥5.2 mmol/l and/or being
prescribed a lipid-lowering drug were considered as
having hypercholesterolaemia. Hypertension was
defined as high brachial blood pressure (BP) values
(SBP ≥140 mmHg and/or DBP ≥90 mmHg) and/or
prescription of a BP-lowering drug for high BP. Current
smokers were defined as those who had smoked any
tobacco in the previous month. Ejection fraction was
determined using contrast ventriculography. 
Cardiac catheterisation was performed according
to a standard technique. Optimal views of the arteries
from all technically suitable angiograms were
analysed. The absolute values for the minimal lumen
diameter and the reference lumen diameter were
measured at end-diastole. Coronary angiograms were
scored according to the number of diseased arteries.
The three major coronary vessels (the left anterior
descending artery, the circumflex artery, and the right
coronary artery) and their branches were evaluated
for the extent of coronary atherosclerosis. A diseased
artery was defined as >50% stenosis of at least one of
its segments. Significant left main artery stenosis was
coded as two-vessel disease. 
All cardiovascular drugs taken within 24 hours prior
to catheterisation were analysed. The following
medication classes were considered: antiplatelets,
beta-blockers, ACE inhibitors, calcium antagonists,
diuretics, nitrates, statins, fibrates, digitalis, oral
hypoglycaemics and insulin. 
Study end points
Study end points were assessed over a 4.5-year
follow-up period. The primary end point was defined as
cardiovascular death, non-fatal MI, non-fatal stroke, non-
-fatal cardiac arrest, percutaneous coronary intervention
(PCI), coronary artery bypass grafting (CABG) or heart
transplantation. Three secondary end points were
defined as follows: (I) cardiovascular death, non-fatal MI
or non-fatal stroke; (II) cardiovascular death, non-fatal
MI, PCI or CABG; (III) cardiovascular death. 
All cardiovascular events were coded according to
ICD-10. Death was considered as cardiovascular if it
was due to MI (code I21), heart failure (code I50),
cerebrovascular disease (codes I60-I64 and I67-I69) or
other cardiovascular causes (codes I00-I99).
Cardiovascular events which occurred within 24 hours
after coronary angiography (stroke in one patient,
ventricular fibrillation in two patients and sustained
ventricular tachycardia in two patients) were not
included in the present analysis as they were
considered as procedure-related. If myocardial
revascularisation procedures (staged PCI or CABG)
were performed or planned at the time of coronary
angiography they were not considered as end points.
Statistical analysis
Categorical variables are reported as percentages
and continuous variables as means±standard
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deviation. Student’s t-test was used for comparisons of
variables with a normal distribution. In the other cases
Mann-Whitney U test was used. A two-tailed p value of
less than 0.05 was considered to indicate statistical
significance. 
Multivariate logistic analysis was used to assess the
influence of gender on the probability of being
prescribed a cardiovascular drug. All variables from
Table I with a p <0.05 were included in the statistical
model. Similarly, multivariate logistic analysis was used
to determine the effect of gender on the frequency of
PCI and CABG. All variables from Tables I and II with 
a p <0.05 were included in the model in this part of the
analysis. 
Kaplan-Meier curves and log-rank test were used
to determine the gender – event-free survival
relationship in univariate analysis. Cox’s proportional
hazards models were used to determine the
independent effects of gender on the occurrence of
primary and secondary end points in multivariate
analysis. In order to compare the prognostic
significance of gender we included all variables from
Tables I and II with a p <0.05. All data were analysed
using the STATISTICA 6.0 software (StatSoft, Inc.,
Tulsa, USA). The institutional ethics committee
approved the protocol of the study.
Results
The study group consisted of 960 patients
undergoing non-emergency coronary angiography.
Study end points were ascertained for 925 patients.
Furthermore, only the cause and date of death were
obtained for 3 participants, and only the date of death
was obtained for one patient. Thirty-one (3.2%)
patients were lost to follow-up. Data from 928 (96.7%)
cases were analysed when cardiovascular death was
taken into account and 925 (96.4%) patients were
included in the analysis when the other end points
were considered. 
We examined a possible bias in the formation of the
analysed population by comparing it with respect to
age, gender, risk factors and heart failure as well as
mean value of ejection fraction with the data of the
population consisting of 31 patients for whom we had
no follow-up information and one person with only the
date of death known. These comparisons showed no
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Variable Men Women p
(N=740) (N=188)
Age (years) 57.5±10.0 60.6±9.2 <0.001
Smoking 
previous 438 (59.2%) 54 (28.7%) <0.001
active 101 (13.6%) 12 (6.4%) <0.01
Hypertension 537 (72.6%) 165 (87.8%) <0.001
Hypercholesterolemia 619 (83.6%) 161 (85.6%) NS
Diabetes 107 (14.5%) 40 (21.3%) <0.05
Heart failure 48 (6.5%) 12 (6.4%) NS
Previous myocardial infarction 468 (63.2%) 124 (66.0%) NS
Previous PCI 65 (8.8%) 16 (8.5%) NS
Previous CABG 11 (1.5%) 1 (0.5%) NS
Body mass index [kg/m2] 27.3±3.5 28.0±4.6 <0.05
Left ventricular ejection fraction [%] 54.4±12.5 56.8±11.6 <0.05
Heart rate (per minute) 65.7±10.7 69.8±13.5 <0.001
Total cholesterol [mmol/l] 5.4±1.1 5.6±1.2 <0.05
HDL cholesterol [mmol/l] 1.2±0.3 1.3±0.3 <0.001
LDL cholesterol [mmol/l] 3.3±1.0 3.4±1.2 NS
Triglycerides [mmol/l] 2.1±1.3 2.0±1.0 NS
Fasting glucose [mmol/l] 5.5±1.4 5.8±2.4 <0.05
Creatinine [μmol/l] 97.5±38.1 89.7±63.5 <0.05
Table I. Characteristics of the analysed population (N=928)
Abbreviations: PCI – percutaneous coronary intervention, CABG – coronary artery bypass grafting
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statistically significant differences with respect to all
the above factors.
Among study participants with the follow-up data
available 188 (20.3%) were women and 740 (79.7%) men.
The mean age was 58.1±9.9 years. Clinical characteristics
of the study population are given in Table I. Seventy-two
(9.7%) men and 26 (13.8%) women were aged over 70
years (p=NS). Obesity (body mass index ≥30.0 kg/m2) was
found in 157 (20.2%) men and 54 (28.8%) women 
(p <0.05), while 381 (51.5%) men and 95 (50.5%) were
overweight (body mass index 25.0-30.0 kg/m2). Thirty-
seven (19.7%) women and 96 (13.0%) men (p <0.05) had
suffered from acute coronary syndrome 7-90 days before
index coronary angiography. 
The frequency of drug use is given in Table II. The
effect of gender on the probability of being prescribed
cardiovascular drugs after multiple adjustments is
shown in Figure 1. Female gender was independently
related to a higher prescription rate of beta-blockers,
ACE inhibitors, calcium antagonists and insulin. 
On the basis of coronary angiography one-vessel
IHD was found in 213 (28.8%) men and 59 (31.4%)
women (p=NS), two-vessel disease in 212 (28.6%) men
and 44 (23.4%) women (p=NS), and three-vessel
disease in 282 (38.1%) men and 69 (36.7%) women
(p=NS), whereas 33 (4.5%) men and 16 (8.5%) women
(p=NS) had no significant atherosclerotic lesion in the
coronary tree. Among men with no significant stenosis
in the epicardial arteries, 31 (91.9%) had a history of MI
and 3 (9.1%) had undergone PCI. Among women with
no significant stenosis 15 (93.8%) had suffered from MI
and 1 (6.3%) female was after previous PCI. 
Out of 707 men and 172 women with significant 
(> 50%) lesions in the coronary arteries, 258 (36.5%) men
and 67 (39.0%) women were treated conservatively
(p=NS), 292 (41.3%) men and 67 (39.0%) women
underwent PCI (p=NS), and 157 (22.2%) men and 
38 (22.1%) women (p=NS) underwent CABG. The effect of
gender on the probability of undergoing myocardial
revascularisation after multiple adjustments is shown
in Figure 2. Gender was not independently related to
the frequency of PCI or CABG. Among PCI patients the
procedure was not successful in 36 (12.3%) men and
7 (10.4%) women (p=NS), mostly in those with chronic
total occlusions. Of those with successful procedure





Antiplatelets 720 (97.3%) 186 (98.9%) NS
Beta-blockers 622 (84.1%) 170 (90.4%) <0.05
ACE  inhibitors 399 (53.9%) 130 (69.1%) <0.001
Calcium antagonists 99 (13.4%) 46 (24.5%) <0.001
Diuretics 139 (18.8%) 55 (29.3%) <0.01
Nitrates 612 (82.7%) 149 (79.3%) NS
Statins 358 (48.4%) 99 (52.7%) NS
Fibrates 25 (3.4%) 8 (4.3%) NS
Digoxin 18 (2.4%) 3 (1.6%) NS
Insulin 32 (4.3%) 21 (11.1%) <0.001
Oral hypoglycemics 48 (6.5%) 14 (7.4%) NS
Antiplatelets 3.53 (0.81-12.9)
Beta-blockers 1.89 (1.08-3.29)
ACE  inhibitors 1.47 (1.01-2.16)







Oral hypoglycemics 1.06 (0.54-2.08)
Figure 1. The odds ratios and 95% confidence
intervals of being prescribed cardiovascular
drug associated with female gender
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127 men (49.6%) and 30 (50.0%) women (p=NS)
underwent stent implantation. No drug-eluting stent
was used in the study population. 
During a mean follow-up time of 52.8±19.4 months
(53.0±19.0 months in men vs. 52.2±21.1 months in
women; p=NS) 87 deaths (69 in men and 18 in women;
p=NS) were recorded. The mean follow-up of those
who did not die was 55.6±17.0 months (55.6±16.8
months in men vs. 55.7±17.7 months among women;
p=NS). During the follow-up there were 55 (7.4%)
cardiovascular deaths among men and 15 (8.0%)
among women (p=NS), 73 (9.9%) men and 13 (7.0%)
women suffered from MI (p=NS), whereas 18 (2.4%)
men and 6 (3.2%) women suffered from from strokes.
Six (3.2%) women and 20 (2.7%) men underwent CABG
(p=NS) whereas 16 (8.6%) women and 98 (13.3%) men
underwent PCI (p=NS). Additionally, one non-fatal
cardiac arrest occurred in a woman and one man
underwent heart transplantation. 
Primary end point
The primary end point occurred in 191 (25.9%) men
and 44 (23.5%) women (the complication rate was
5.9%/year in men and 5.4%/year in women; p=NS). The
Kaplan-Meier curves of survival free of the primary end
point are shown in Figure 3A. The risk of primary end
point occurrence associated with female gender after
multivariate adjustments is shown in Figure 4. None of
the analyses showed female gender to be an
independent predictor of the primary end point. When
number of diseased coronary vessels and
revascularisation procedures were incorporated into the
model, gender again was not independently related to
the end point. 
Secondary end points
Secondary end point which consisted of
cardiovascular death or non-fatal MI or non-fatal stroke
occurred in 108 (14.6%) men and 27 (14.4%) women (the
complication rate was 3.3%/year in men and 3.3%/year in
women; p=NS). The Kaplan-Meier curves of survival free
of the end point are shown in Figure 3B. The risk of the
end point associated with female gender after
multivariate adjustments is shown in Figure 4.
The end point which consisted of cardiovascular
death, non-fatal MI, PCI or CABG occurred in 179
(24.3%) men and 39 (20.9%) women (the complication
rate was 5.5%/year in men and 4.8%/year in women;
p=NS). The Kaplan-Meier curves of survival free of the
end point are shown in Figure 3C. The risk of the end
point associated with female gender after multivariate
adjustments is shown in Figure 4. 
Cardiovascular death occurred in 55 (7.4%) men
and 15 (8.0%) women (the cardiovascular mortality rate
was 1.7%/year in men and 1.8%/year in women; p=NS).
The Kaplan-Meier curves are shown in Figure 3D. The
risk of cardiovascular death associated with female
gender after multivariate adjustments is shown in
Figure 4. None of the analyses showed female gender to
be an independent predictor of any of the secondary end
points. When the number of diseased coronary vessels
and revascularisation procedures were incorporated into
the model, gender again was not independently related
to the risk of end point occurrence.
Discussion
The most interesting finding of the present
analysis is that women with IHD were more
frequently treated with cardiovascular drugs when
compared with their male counterparts. In the past
numerous studies were published indicating rather
lower probability of being prescribed cardiovascular
drugs among women with IHD [1, 6, 8, 15]. No major
influence of gender was also reported [5, 19]. Our
results are in concordance with the data from the
Cracovian Program for Secondary Prevention of
Ischaemic Heart Disease [20]. Patients hospitalised in
six cardiac departments took part in this study. Quite
similar differences were found in this population in
respect of antiplatelets (82.2% in women vs. 81.3% in
men), beta-blockers (64.7% vs. 60.3%) and lipid-
lowering agents (40.7% vs. 37.3%) prescription rates
[20]. In recent years the problem of IHD management
quality in women has been emphasised quite often
[21, 22]. In addition, such campaigns as “Women at
Heart” in Europe or “Go red for women” in the United
States have increased the awareness of health
professionals. Many symposia and conferences
focusing on the management of women with heart
diseases have also been organised in recent years in
Poland. Probably our results can be at least partly
explained by the effects of the above events. 
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PCI 1.01 (0.69-1.49)
CABG 0.91 (0.57-1.48)
Figure 2. The odds ratios and 95% confidence
intervals of the probability of PCI and CABG
associated with female gender
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Figure 3. The Kaplan-Meier curves of event-free survival in men and women
Primary end point CV death, MI or stroke
CV death, MI, PCI or CABG Cardiovascular death











































Primary end point 0.94 (0.067-1.34)
CV death, MI or stroke 1.08 (0.69-1.70)
CV death, MI, PCI or CABG 0.90 (0.62-1.30)
Cardiovascular death 1.38 (0.74-2.59)
Figure 4. The hazard ratios and 95% confidence intervals of primary and secondary end points associated
with female gender
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In contrast to several previous reports [2, 6] we did
not find any gender-related bias in the proportion of
patients undergoing revascularisation procedures. It
should be, however, underlined that only patients with
confirmed (significant stenosis in coronary
angiography and/or MI in the history) IHD were
included in the present analysis. The inclusion of the
whole patient population undergoing coronary
angiography in the analysis would probably result in 
a significant difference in revascularisation rates
between men and women. This is because a much
higher proportion of women undergoing coronary
angiography are found to have no significant
atherosclerosis in the coronary tree and these women
are not selected for revascularisation procedures. 
As women differ from men in respect of a number
of clinical features [3] it is essential to perform an
appropriate statistical analysis to draw reasonable
conclusions. Ghali et al. identified gender as a predictor
of revascularisation after adjustments for clinical
variables with the exception of the extent of coronary
disease and ventricular function but they failed to
show the same association when the extent of
coronary atherosclerosis and ventricular function were
included in the statistical model [23]. To some extent
the same phenomenon was found by Daly et al. [8]. It
should be noted that our results agree with a number
of studies showing no significant gender-related bias
[5, 8]. Among them the analysis of a large set of data
collected in the Euro Heart Survey of Stable Angina
failed to show an independent relationship between
gender and myocardial revascularisation procedures in
European regions other than Northern Europe. 
Also, we did not confirm the previous findings that
women with IHD have higher rate of further
cardiovascular complications [2, 3, 6, 8, 15]. First, most of
the previous reports included patients with acute coronary
syndromes (with or without ST elevation) [2, 3, 6, 15].
Second, the difference in mean age between genders was
smaller in our study population than in the previous
reports [2, 6, 15]. It is known that age is one of the most
important factors influencing the patient’s prognosis.
Indeed, this could explain the difference between our
and previous results. Third, the significantly higher rate
of cardiovascular drug prescription among women could
decrease the cardiovascular complication rate in women
to the level of men. It was also suggested that women
analysed in studies which showed higher risk in women
with acute coronary syndromes, might not be
representative for the whole population of women with
acute coronary syndromes [11]. Our results agree with a
number of studies showing no major gender-related
differences in cardiovascular risk [5, 9, 13, 16, 17, 19].
However, it should be underlined that many investigators
found even much greater risk of major cardiovascular
events in men [1, 14, 24]. 
Coronary stenosis >50% was considered as
significant. A similar definition was used in
international registries [8] as well as in many original
contributions [25]. Although the definition of significant
stenosis as over 70% would decrease the number of
patients qualified as those with CAD it would not
change our main results. We repeated all analyses
using the definition “>70” and we obtained the same
results. 
Mean age in the European registries was slightly
higher than in the present study group: in the Euro
Heart Survey on Coronary Revascularization the mean
age was 63 years and in the Euro Heart Survey of
Stable Angina – 62 years in women and 60 years in
men [8, 26]. Average length of life is several years
lower in Poland than in most other European
countries. It was also shown that mean age of IHD
onset is lower in Poland than in Western Europe
countries. Indeed, this could explain the above
differences in the mean study population age. It
should also be noted that a single-centre analysis
from Szczecin showed even lower mean age in
women undergoing coronary angiography (57 years)
[27]. Our findings also agree with the data from the
Cracovian Program for Secondary Prevention of
Ischaemic Heart Disease: mean age in women was 58.8
years whereas in men it was 56.4 years [20]. As patients
older than 70 years were excluded from the Cracovian
Program for Secondary Prevention of Ischaemic Heart
Disease this could induce the difference in mean age
between the present study and the Cracovian Program
populations [20]. 
The proportion of women in the present study is
comparable with the data from the multicentre
Cracovian Program for Secondary Prevention of
Ischaemic Heart Disease (21-22% of those undergoing
coronary revascularisation were women) [28, 29] as
well as from a single-centre analysis from Szczecin [27].
As a significant proportion of women in the group
analysed by Gil and Pawłowski were found to have no
coronary atherosclerosis, the percentage of women
among all patients with IHD was probably below 20%
[27]. Our data agree also with results from the Euro
Heart Survey on Coronary Revascularization [26].
Although the proportion of women in this survey was
24%, after exclusion of those treated for acute
coronary syndromes the percentage of women would
probably decrease to about 20% [26].
Fourteen percent of our study population had
suffered from an acute coronary syndrome 7-90 days
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before index coronary angiography. When we limited
the analysis to this subgroup the results did not vary
significantly (data not shown). 
Study limitations
Data from 928 patients undergoing coronary
angiography were included in the present analysis. It is
possible that the results would differ if we analysed 
a much bigger group. However, as female gender was
related to significantly higher cardiovascular drug
prescription rates there is an extremely low probability
that the results would be reversed. On the other hand,
the gender-survival relationship analysis could indeed
produce different results if the analysed population
was much greater. 
Only patients undergoing non-emergency coronary
angiography were included in the study. It is possible that
inclusion of non-invasively managed coronary patients
would change our results. Moreover, as the present
analysis is a single centre study it is possible that the study
population was not representative for all men and women
with IHD undergoing non-emergency coronary
angiography. Indeed, some investigators reported quite
different results. Nevertheless, we showed that it is
possible to provide at least similar quality of medical care
to females and males, and that it can lead to comparable
prognosis in women and men. 
Conclusions
Female gender was independently related to higher
prescription rate of beta-blockers, ACE inhibitors and
calcium antagonists. No gender-related bias was found
in respect of myocardial revascularisation. Gender was
not an independent factor influencing event-free
survival in patients with IHD undergoing non-
emergency coronary angiography. 
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Płeć nie wpływa na częstość wykonywania 
rewaskularyzacji mięśnia sercowego ani na rokowanie 
u chorych ze stabilną chorobą niedokrwienną serca 
Piotr Jankowski, Kalina Kawecka-Jaszcz, Danuta Czarnecka, Leszek Bryniarski, 
Małgorzata Brzozowska-Kiszka, Beata Kić-Wilk, Grzegorz Dymek, Ewa Kopacz, Tadeusz Królikowski, 
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S t r e s z c z e n i e
Wstęp: Wyniki badań oceniających wpływ płci na rokowanie u pacjentów z ostrymi zespołami wieńcowymi są sprzeczne.
Natomiast wyniki badań oceniających wpływ płci na rokowanie u pacjentów ze stabilną chorobą niedokrwienną serca (IHD) są
nieliczne i również rozbieżne. W Polsce nie analizowano dotąd wpływu płci na rokowanie w tej grupie chorych. Także wyniki
badań dotyczących relacji między płcią a częstością stosowania leków kardiologicznych oraz częstością rewaskularyzacji mię-
śnia sercowego nie są zgodne. 
Cel: Ocena wpływu płci na częstość stosowania leków kardiologicznych, częstość wykonywania zabiegów angioplastyki
wieńcowej (PCI) oraz operacji pomostowania aortalno-wieńcowego (CABG), a także rokowanie u osób z IHD poddawanych ko-
ronarografii w trybie planowym. 
Metodyka: Do badania zakwalifikowano 960 kolejnych pacjentów z IHD poddawanych koronarografii. Chorobę niedo-
krwienną serca zdefiniowano jako co najmniej jedno zwężenie >50% w tętnicy wieńcowej lub zawał mięśnia sercowego lub re-
waskularyzację w wywiadzie. Występowanie powikłań sercowo-naczyniowych oceniono u 925 osób (738 mężczyzn oraz 187 ko-
biet). Pierwszorzędowy punkt końcowy zdefiniowano jako zgon z przyczyn sercowo-naczyniowych, zawał serca, udar mózgu,
zatrzymanie krążenia, PCI, CABG lub transplantację serca.  
Wyniki: Kobiety były starsze od mężczyzn (60,6±9,2 lat vs 57,5±10,0 lat, p <0,05). Nadciśnienie tętnicze oraz cukrzyca wy-
stępowały istotnie częściej u kobiet (odpowiednio 87,7% vs 72,6%, p <0,05 oraz 21,3% vs 14,5%, p <0,05), a mężczyźni częściej
palili (13,6% vs 6,4%, p <0,05). Nie było istotnych różnic pod względem częstości występowania hipercholesterolemii (85,6%
vs 83,6%), niewydolności serca (6,4% vs 6,5%), zawału serca w wywiadzie (66,0% vs 63,2%), PCI w wywiadzie (8,5% vs 8,8%)
ani CABG w wywiadzie (0,5% vs 1,5%). Nie stwierdzono również istotnej różnicy pod względem liczby zwężonych tętnic wień-
cowych. Płeć żeńska, po uwzględnieniu zmiennych zakłócających, wiązała się z większą częstością stosowania beta-blokerów
[iloraz szans 1,89 (95% CI 1,08–3,29)], inhibitorów enzymu konwertującego [1,47 (1,01–2,16)] oraz blokerów kanału wapniowe-
go [1,65 (1,08–2,53)], nie stwierdzono natomiast istotnego wpływu płci na częstość wykonywania PCI [1,01 (0,69–1,49)] oraz
CABG [0,91 (0,57–1,48)]. Średni czas obserwacji wyniósł 55,6±16,8 mies. W okresie obserwacji zmarło 87 osób (69 mężczyzn
oraz 18 kobiet), w tym 70 [55 (7,4%) mężczyzn oraz 15 (8,0%) kobiet] z przyczyn sercowo-naczyniowych. Pierwszorzędowy punkt
końcowy wystąpił u 25,9% mężczyzn oraz 23,5% kobiet (p=NS). W analizie wieloczynnikowej płeć żeńska nie była związana
z częstością wystąpienia pierwszorzędowego punktu końcowego [0,94 (0,67–1,34)]. Nie była również istotnie związana z czę-
stością wystąpienia drugorzędowych punktów końcowych: zgonu z przyczyn sercowo-naczyniowych, zawału serca lub udaru
mózgu [1,08 (0,69–1,70)]; zgonu z przyczyn sercowo-naczyniowych, zawału serca lub rewaskularyzacji [0,90 (0,62–1,30)]; zgonu
z przyczyn sercowo-naczyniowych [1,38 (0,74–2,59)]. 
Wnioski: Kobiety były istotnie częściej leczone beta-blokerami, inhibitorami enzymu konwertującego oraz antagonistami
wapnia. Nie stwierdzono natomiast istotnego wpływu płci na częstość wykonywania rewaskularyzacji mięśnia sercowego ani
na rokowanie. 
Słowa kluczowe: choroba niedokrwienna serca, płeć, ryzyko sercowo-naczyniowe, jakość opieki medycznej 
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